Ketorolac Should Be Avoided in Patients with Aortic Aneurysm Presenting with Acute Gout
In a patient with an aortic aneurysm experiencing an acute gout flare, ketorolac is contraindicated due to cardiovascular risks and should be replaced with oral corticosteroids (prednisolone 30-35 mg daily for 3-5 days) as the safest first-line option.
Rationale for Avoiding Ketorolac
The FDA label for ketorolac explicitly warns about increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke with NSAID use 1. The label specifically states that "patients with known CV disease or risk factors for CV disease may be at greater risk" 1. An aortic aneurysm represents established cardiovascular disease with inherent risk of rupture, dissection, and thrombotic complications—making ketorolac particularly hazardous in this population.
Additionally, ketorolac carries significant hemorrhage risk. The FDA label warns that it "affects platelet aggregation" and notes that "postoperative hematomas and other signs of wound bleeding have been reported" 1. In the context of an aortic aneurysm, any medication that impairs hemostasis poses catastrophic risk should the aneurysm rupture or require emergent surgical intervention.
Recommended Treatment Algorithm
First-Line: Oral Corticosteroids
- Prednisolone 30-35 mg daily for 3-5 days is the optimal choice 2
- Equivalent analgesic efficacy to NSAIDs without cardiovascular or bleeding risks
- EULAR guidelines establish this as a co-equal first-line option with NSAIDs 2
- No contraindications in aortic aneurysm patients
Second-Line: Colchicine (if within 12 hours of flare onset)
- Loading dose of 1 mg followed by 0.5 mg one hour later 2
- Critical caveat: Avoid if patient has severe renal impairment (GFR <30 mL/min) or is taking strong P-glycoprotein/CYP3A4 inhibitors (cyclosporin, clarithromycin) 2
- Does not carry the cardiovascular or bleeding risks of NSAIDs
Third-Line: Intra-articular Corticosteroid Injection
- If a single joint is involved, aspiration and injection of corticosteroids is appropriate 2
- Avoids systemic medication risks entirely
Why NSAIDs (Including Ketorolac) Are Inappropriate
While ketorolac has demonstrated efficacy for acute gout in emergency department studies 3, 4, these trials excluded patients with significant cardiovascular disease. The 2017 EULAR guidelines recommend NSAIDs as first-line therapy but explicitly state they should be used "with care" and note the importance of screening for cardiovascular comorbidities 2.
The FDA mandates that ketorolac be limited to ≤5 days due to "potential of increasing the frequency and severity of adverse reactions" 1. The cardiovascular warnings are unequivocal: NSAIDs "can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events" 1.
Important Clinical Pitfall
Do not be misled by emerging research showing ketorolac may reduce mortality in open AAA repair 5 or that it's being studied in acute type A aortic dissection 6. These studies involve controlled perioperative use in monitored settings—fundamentally different from outpatient management of acute gout. The study protocols involve single doses with intensive monitoring, not the multi-day courses used for gout flares.
Additional Considerations
The 2024 ESC guidelines emphasize that patients with aortic disease require aggressive cardiovascular risk factor management 7. Introducing an NSAID that increases thrombotic and bleeding risk runs counter to this principle. Furthermore, recent epidemiologic data suggests bidirectional associations between gout and AAA 8, 9, reinforcing the need for cautious medication selection in this population.
The bottom line: Oral corticosteroids provide equivalent pain relief without the cardiovascular and hemorrhagic risks that make ketorolac unacceptable in patients with aortic aneurysms.